91 results
Page 4 of 5
8-K
8ddna6s
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
0hmhx0x
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
wnr68gtj5b9s17
5 Nov 20
Sutro Biopharma Reports Third Quarter 2020 Financial Results
7:05am
8-K
EX-99.1
6u39tx6yz
6 Aug 20
Sutro Biopharma Reports Second Quarter 2020 Financial Results
7:03am
424B5
ekxfo re1frcskzte
12 May 20
Prospectus supplement for primary offering
5:02pm
8-K
EX-99.1
e6wb 2byj
11 May 20
Sutro Biopharma Reports First Quarter 2020 Financial Results
4:27pm
424B5
584wke10ci6h7vy6ng
11 May 20
Prospectus supplement for primary offering
4:12pm
8-K
gtjl08dj5 qo
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
k376qb
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
dvn2tdigpm3dos dqz
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
8-K
EX-99.1
xoiry
8 Nov 19
Sutro Biopharma Reports Third Quarter 2019 Financial Results
8:00am
8-K
EX-99.1
xqrg3ns5 1g
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
424B5
isfg6m8ed0wm4
11 Oct 19
Prospectus supplement for primary offering
4:22pm
S-3
ior1tu wd
4 Oct 19
Shelf registration
4:06pm